Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Lymphoma

CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells

Leukemia volume 23, pages 1329–1336 (2009)Cite this article

A Corrigendum to this article was published on 15 July 2009

Abstract

We studied the effect of CMC-544, the calicheamicin-conjugated anti-CD22 monoclonal antibody, used alone and in combination with rituximab, analyzing the quantitative alteration of target molecules, that is, CD20, CD22, CD55 and CD59, in Daudi and Raji cells as well as in cells obtained from patients with B-cell malignancies (BCM). Antibody inducing direct antiproliferative and apoptotic effect, complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) were tested separately. In Daudi and Raji cells, the CDC effect of rituximab significantly increased within 12 h following incubation with CMC-544. The levels of CD22 and CD55 were significantly reduced (P<0.001 in both cells) after incubation with CMC-544, but CD20 level remained constant or increased for 12 h. Similar results were obtained in cells from 12 patients with BCM. The antiproliferative and apoptotic effect of CMC-544 were greater than that of rituximab. The ADCC of rituximab was not enhanced by CMC-544. Thus, the combination of CMC-544 and rituximab increased the in vitro cytotoxic effect in BCM cells, and sequential administration for 12 h proceeded by CMC-544 was more effective. The reduction of CD55 and the preservation of CD20 after incubation with CMC-544 support the rationale for the combined use of CMC-544 and rituximab.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Fisher RL, Shah P . Current trends in large cell lymphoma. Leukemia 2003; 17: 1948–1960.

    Article  CAS  Google Scholar 

  2. Fanale MA, Younes A . Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Drugs 2007; 67: 333–350.

    Article  CAS  Google Scholar 

  3. Coiffier B . Rituximab therapy in malignant lymphoma. Oncogene 2007; 26: 3603–3613.

    Article  CAS  Google Scholar 

  4. Montserrat E, Moreno C, Esteve J, Urbano-Ispizua A, Giné E, Bosch F . How I treat refractory CLL. Blood 2006; 107: 1276–1283.

    Article  CAS  Google Scholar 

  5. Smith MR . Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003; 22: 7359–7368.

    Article  CAS  Google Scholar 

  6. Bannerji R, Kitada S, Flinn IW, Pearson M, Young D, Reed JC et al. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. J Clin Oncol 2003; 21: 1466–1471.

    Article  CAS  Google Scholar 

  7. Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001; 98: 3383–3389.

    Article  CAS  Google Scholar 

  8. Macor P, Tripodo C, Zorzet S, Piovan E, Bossi F, Marzari R et al. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res 2007; 67: 10556–10563.

    Article  CAS  Google Scholar 

  9. Dahle J, Borrebaek J, Jonasdottir TJ, Hjelmerud AK, Melhus KB, Bruland ØS et al. Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate. Blood 2007; 110: 2049–2056.

    Article  CAS  Google Scholar 

  10. DiJoseph JF, Amelino DC, Boghhaert ER, Khandke K, Dougher MM, Sridharan L et al. Antibody-targeted chemotherapy with CMC544: a CD22-tageted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 2004; 103: 1807–1814.

    Article  CAS  Google Scholar 

  11. Zein N, Sinha AM, McGahren WJ, Ellestad GA . Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 1988; 240: 1198–1201.

    Article  CAS  Google Scholar 

  12. Fayad L, Patel H, Verhoef G, Cruczman M, Foran J, Gine E et al. Clinical activity of the immunoconjugate CMC-544 in B-cell malignancies: Preliminary report of the expanded maximum tolerated dose (MTD) cohort of a phase 1 study. Blood 2006; 108: 766a, absr. #2711.

    Google Scholar 

  13. DiJoseph JF, Dougher MM, Kalyandrug LB, Armellino DC, Boghaert ER, Hamann PR et al. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. Clin Cancer Res 2006; 12: 242–249.

    Article  CAS  Google Scholar 

  14. Sugimoto Y, Sato S, Tsukahara S, Suzuki M, Okochi E, Gottesman MM et al. Coexpression of a multidrug resistance gene (MDR1) and herpes simplex virus thymidine kinase gene in a bicistronic retroviral vector Ha-MDR-IRES-TK allows selective killing of MDR1-transduced human tumors transplanted in nude mice. Cancer Gene Ther 1997; 4: 51–58.

    CAS  PubMed  Google Scholar 

  15. Matsui H, Takeshita A, Naito K, Shinjo K, Shigeno K, Maekawa M et al. Reduced effect of gemtuzumab ozogamicin (CMC-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. Leukemia 2002; 16: 813–819.

    Article  CAS  Google Scholar 

  16. Yasukawa M, Arai J, Kakimoto M, Sakai I, Kohno H, Fujita S . CD20-positive adult T-cell leukemia. Am J Hematol 2001; 66: 39–41.

    Article  CAS  Google Scholar 

  17. Toba K, Hanawa H, Fuse I, Sakaue M, Watanabe K, Uesugi Y et al. Difference in CD22 molecules in human B cells and basophils. Exp Hematol 2002; 30: 205–211.

    Article  CAS  Google Scholar 

  18. Hatanaka M, Seya T, Matsumoto M, Hara T, Nonaka T, Inoue N et al. Mechanisms by which the surface expression of the glycosyl-phosphatidylinositol- anchored complement regulatory proteins decayacceleratingfactor (CD55) and CD59 is lost in human leukaemia cell lines. Biochem J 1996; 314: 969–976.

    Article  CAS  Google Scholar 

  19. Naito K, Takeshita A, Shigeno K, Nakamura S, Fujisawa S, Shijo K et al. Caliceamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab ozogamicin, CMC676) shows cytocydal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia 2000; 14: 1436–1443.

    Article  CAS  Google Scholar 

  20. Takeshita A, Shinjo K, Naito K, Matsui H, Sahara N, Shigono K et al. Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells. Leukemia 2005; 19: 1306–1311.

    Article  CAS  Google Scholar 

  21. Takei K, Yamazaki T, Sawada U, Ishizuka H, Aizawa S . Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines. Leuk Res 2006; 30: 625–631.

    Article  CAS  Google Scholar 

  22. Karasawa S, Araki T, Yamamoto-Hino M, Miyawaki A . A green-emitting fluorescent protein from Galaxeidae coral and its monomeric version for use in fluorescent labeling. J Biol Chem 2003; 278: 34167–34171.

    Article  CAS  Google Scholar 

  23. Cheson BD . Monoclonal antibody therapy for B-cell malignancies. Semin Oncol 2006; 33: S2–S14.

    Article  CAS  Google Scholar 

  24. van der Kolk LE, Grillo-López AJ, Baars JW, van Oers MH . Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy. Leukemia 2003; 17: 1658–1664.

    Article  CAS  Google Scholar 

  25. Ziller F, Macor P, Bulla R, Sblattero D, Marzari R, Tedesco F . Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59. Eur J Immunol 2005; 35: 2175–2183.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We express our sincere gratitude to Wyeth Pharmaceuticals Inc. (USA) for their continuous support and for reviewing the article, and to Ms Yoshimi Suzuki, Ms Noriko Anma and Dr Kiyoshi Shibata (Equipment Center at Hamamatsu University School of Medicine) for technical assistance. This study was supported by Japanese grants-in-aid from the Ministry of Education, Culture, Sports, Science and Technology (19590552, 17590489).

Author information

Authors and Affiliations

  1. Department of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu, Higashi-ku, Japan

    A Takeshita, N Yamakage & M Maekawa

  2. Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Higashi-ku, Japan

    A Takeshita, K Shinjo, T Ono, I Hirano, S Nakamura, K Shigeno & K Ohnishi

  3. Department of Hematology, Yaizu City Hospital, Yaizu, Japan

    T Tobita

  4. Department of Infectious Diseases, Nagoya University, Nagoya, Chikusa-ku, Japan

    H Kiyoi

  5. Department of Hematology and Oncology, Nagoya University, Nagoya, Chikusa-ku, Japan

    T Naoe

  6. Graduate School of Pharmaceutical Sciences, Keio University, Tokyo, Minato-ku, Japan

    Y Sugimoto

  7. Aichi Cancer Center, Nagoya, Chikusa-ku, Japan

    R Ohno

Authors
  1. A Takeshita
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N Yamakage
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Shinjo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T Ono
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I Hirano
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K Shigeno
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T Tobita
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M Maekawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. H Kiyoi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. T Naoe
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. K Ohnishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Y Sugimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. R Ohno
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Takeshita.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Takeshita, A., Yamakage, N., Shinjo, K. et al. CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells. Leukemia 23, 1329–1336 (2009). https://doi.org/10.1038/leu.2009.77

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2009.77

Keywords

This article is cited by

Search

Advanced search

Quick links